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Summary 
Previously we showed that motility-rehted protein (MRP-1) is an antigen recognized by monoclonal 
antibody (mAb) M31-15 inhibiting cell motility and that the sequence of MKP-1 coincides with 
that of CD9. In the present study, plasmid was constructed in which human MRP-1/CD9 cDNA 
is expressed under the control of the Abelson routine leukemia virus promoter sequence. The 
expression plasmid for MRP-1/CD9 was introduced into Chinese hamster ovary cells, human 
lung adenocarcinoma cell line MAC10 (MKP-1 positive), and human myeloma cell line ARH77 
(MRP-1 negative). All of the MRP-1/CD9 (over)expressing clones obtained from these transfected 
cells showed suppressed cell motility (penetration and phagokinetic track assays) depending on 
the degree of expression of MRP-1/CD9. Overexpression of MRP-1/CD9 by MAC10 cells resulted 
in the suppression of cell motility (maximally 73%) associated with considerable inhibition of 
the cell growth (maximally 48%). However,  the inhibition of the growth of MAC10 cells by 
mAb M31-15 was <17% at an antibody concentration of 1-5 #g/m1, which inhibits cell motility 
by >90%. These results suggest that MRP-1/CD9 directly regulates cell motility and may also 
affect ceU growth. Effects on metastasis by the expression  of MRP-1/CD9 were investigated 
with mouse melanoma BL6 ceLls-~S,  LB/c nu/nu  mouse system.  Metastatic potential of all 
transformants expressing MRP-1/CD9 was lower than that of parent BL6 cells. 
T 
he human leukocyte-associated antigen CD9 was discov- 
ered as a human B lymphocyte differentiation antigen, 
and it was initially considered to be specific for acute lym- 
phoblastic leukemic cells; however, CD9 antigen has been 
found to be widely expressed on many nonhemopoietic  tissues 
including smooth muscle, fibroblasts, and various cancers (1, 
2).  Indeed, it is strongly expressed  on platelets,  where it 
mediates platelet activation and aggregation upon binding 
with mAbs (3), but its essential role in nonhemopoietic cells 
has not yet been clarified. Recently, we obtained the mAb 
M31-15 inhibiting cell motility and cloned motility-related 
protein (MRP-1) 1 eDNA recognized by this mAb (4). The 
sequence of MRP-1 was quite similar to that of CD9 (5). 
Sequence analysis revealed that MRP-1 is highly similar to 
B cell surface antigen CD37 (6),  melanoma-associated an- 
tigen ME491 (7), the target of the antiproliferative antibody 
TAPA-1 (8), the human tumor-associated antigen CO-029 
1 Abbreviations used in this paper: DHFK, dihydrofolate reductase; MRP-1, 
motility-related  protein. 
(9), and Sm23 antigen of the trematode parasite Schistosome 
mansoni (10). MRP-1 is a cell surface protein expressed at a 
molecular mass of 25 and 28 kD in most solid human tumor 
cell lines, except hepatocellular carcinomas, but not in ham- 
ster or mouse cell lines (4).  The essential function of this 
family of unique transmembrane proteins is unknown, espe- 
cially in relation to cancer. As the first approach to determine 
the function of MKP-1/CD9, the MKP-1/CD9 cDNA was 
introduced into several cell lines, and the properties of the 
stable transformants were analyzed. 
Materials and Methods 
Cells andPlasmids.  MAC10  (a human lung adenocarcinoma  cell 
line) (4), Raji cells (a human Burkitt's lymphoma cell  line), ARI-I77 
(a human myeloma cell line) (11), and BL6 (a mouse melanoma 
cell line) (12) were cultured in RPM11640 supplemented  with 10% 
FCS, 10 mM Hepes,  and 100 #g/ml of  kanamycin  (growth medium). 
Dihydrofolate reductase-negative  (DHFR-) CHO cells (13) were 
cultured  in Ham's F-12 instead  of RPM11640. To construct pTB1442 
(Fig. 1), the 1.1-kb EcoKI fragment containing the human M1LP- 
1/CD9 eDNA was inserted into pTBD08, which was constructed 
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with SaI-HindIII. The fragment (2.7 kb) containing MRP-1/CD9 
cDNA was ligated with the 4.1-kb SalI-HindlII fragment containing 
the DHFK gene from pTB348 (14). The control plasmid was con- 
structed in the same manner without inserting MRP-1/CD9 into 
pTB1308. In some experiments, the 1.9-kb HindlII fragment con- 
taining the neomycin phosphotransferase gene prepared from the 
pneoEK5 plasmid was inserted into pTB1442 and used (pTB1503). 
Transfection and Isolation of Stable Clones.  A confluent monolayer 
of DHFK-  CHO  cells in  a  6-cm  dish  was  transfected with 
pTB1442 DNA (10 #g) by the calcium phosphate coprecipitation 
procedure (15, 16). The cells were cultured in DME containing 
proline (35 rag/liter) and dialyzed FCS, and growing colonies were 
selected. ARH77, Raji, MAC10, and BL6 ceils were transfected 
by the electroporation method (17) using a genepulser (Bio-Rad 
Laboratories, Richmond, CA). Briefly, the cell suspensions (5  x 
106/0.5 ml of RPMI 1640) were mixed with 20 #g of pTB1503 
DNA for ARH77, Raji, and BL6 cells, or with 20 #g of pTB1442 
and 2 #g of pRc/CMV (Invitrogen,  San Diego, CA) DNA for 
MAC10 ceils, cooled on ice for 5 min, and pulsed at 0.3 Kv/500 
#F. The cells transfected with DNA were suspended at 2.5  x 
10Vml in  the growth medium  and seeded in  microplates (100 
#l/well). After incubating for 2 d, the medium was replaced with 
fresh medium containing 1 mg/ml of  G418 (geneticin sulfate; Sigma 
Chemical Co., St. Louis, MO). After 2 or 3 wk, the cells growing 
at a single colony were selected. 
Determination of CeU Motility.  Cell motility was determined by 
two assay systems, cell penetration (18) and phagokinetic track (19), 
as described previously (4). In the former system, cell migration 
was determined by the modified method. Briefly, 600 #1 of RPMI 
1640, 0.1% FCS was poured in the lower compartment of a Tram- 
well (pore size, 5-#m diameter; Costar, Cambridge, MA), and cell 
suspensions (5  x  104 cells/100 #1 of RPMI 1640, 0.05% FCS) 
were placed  in the upper chamber. After culturing at 37~  for 16 h, 
cells penetrating  into the lower chamber were counted. 
CellAdhesion.  Cell adhesion to fibronectin (human species; Sei- 
kagaku Corp., Tokyo,  Japan) and hminin (mouse species; Seikagaku 
Corp.) was measured. The coating of plates with fibronectin and 
laminin (Maxisorp F96; Nunc, Roskilde, Denmark) was performed 
at 0.4 #g/well. Cells harvested with trypsin were washed once with 
KPMI 1640, 1% FCS, suspended at 4  x  10S/ml, and seeded in 
the fibronectin- or laminin-coated plates (100 #l/well). After in- 
cubating  at  37~  for 4 h,  nonadherent  cells were removed by 
washing two times with 150 #1 of PBS (137 mM NaC1, 2.7 mM 
KC1, 8.1 mM NazHPO4, 1.5 mM KH2PO4, pH 7.4). Each well 
was filled with 100 #1 of KPMI 1640, 1% FCS, then 20 #1 of  MTT 
(Sigma Chemical Co.) solution (5 mg/ml in PBS) was added to 
each well followed by incubation at 37~  for 4 h. 100 #1 of SDS 
solution (10% SDS in 0.01 N HC1) was added to each well fol- 
lowed by incubation at 37~  for 24 h. The absorbance was then 
read at 590 nm. The assay was performed in quadruplicate. 
Determination of MRP-1/CD9 Content.  MRP-1/CD9 content 
was determined by cytofluorometry  (20) and cell ELISA. Cell ELISA 
was performed as follows. Cells were harvested with 0.01% EDTA 
and washed once with growth medium. Aliquots of 10  s cells were 
placed in tubes, the medium was removed by aspiration, and 100 
#1 of medium  A  (KPMI  1640 containing  1%  FCS and 0.1% 
NAN3) or mAb  M31-15 (2 #g/ml in medium A) was added to 
each tube. After incubation at 0~  for 30 min, the cells  were washed 
four times with 200 #1 of RPMI 1640, 0.1% NAN3. Horseradish 
peroxidase (HILP)-conjugated anti-mouse IgG (100 #1; diluted 
1,000-fold with medium A) was then added to each tube. After 
incubation at 0~  for 30 min, these cells were washed four times 
with 200 #1 of PBS. Freshly prepared substrate solution (200 #g 
of o-phenylenediamine  and 0.05 #1 of H~O2 in 100 #1 of 24.3 mM 
citric acid, 51.4 mM Na2HPO4 [pH 5.0]) was added to each tube 
followed by incubation at room temperature for 10 rain. The reac- 
tion was stopped by adding 200 #1 of 1 N  HzSO4, and aliquots 
of the supematant were transferred to a 96-well plate. The absor- 
bance at 490 nm of each well was read by a microplate reader (450; 
Bio-Rad Laboratories). The concentration of MRP-1/CD9 was ex- 
pressed as relative  concentration, where the concentration of  MAC10 
cells was determined tentatively as 1 U. 
Experimental Metastasis Assay.  Pulmonary metastasis was in- 
duced by intravenous challenge of BALB/c nu/nu mice (n  =  10) 
with 10  s cells. The number of pulmonary metastases was deter- 
mined 14 d after challenge (18). 
Results 
Tra~fection and Isohtion of S~ble Clones.  DHFR-  CHO 
cells were transfected with pTB1442 DNA, and growing colo- 
nies (DHFK +) were selected.  The five clones obtained were 
tested for the expression of MKP-1/CD9 by cytofluorom- 
etry using mAb M31-15. All clones strongly expressed MRP- 
1/CD9 (Fig. 2 A). ARH77 and Raji cells were transfected 
with pTB1503  DNA and selected based upon resistance to 
G418. 10 clones were obtained for each, and four clones for 
AKH77 cells (Fig. 2 B) and five clones for Raji cells (data 
not shown) clearly expressed MRP-1/CDg. MAC10 cells were 
cotransfected with pTB1442 and pRc/CMV DNA and selected 
based upon resistance to G418.14 clones were obtained and 
examined by cytofluorometry, but the degree of expression 
of MRP-1/CD9 was not clear (data not shown). Then, the 
MRP-1/CD9 content on the surface of MAC10 and its clones 
was determined by cell ELISA. Some clones expressed MPK- 
1/CD9 more strongly than the parent cells. Seven clones ex- 
pressing MRP-1/CD9 in different degrees were selected for 
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Figure 1.  Map of the expression  vector  ptB1442. The MR.P-1 cDNA 
(MRP-1), the origin of replication (SV40 or  O, dihydrofolate  reductase 
(DHFR), ampicillin resistance  gene (Apt), and the region of MuLV long 
terminal repeat (LTR) are indicated. 
1232  Suppression  of Cell Motility and Metastasis ~ 
DHFR- CHO /  "'  ,'￿9  CHOI1  1 
eLI 
~ 
""  |;"  CHO/21 
r~.l  rv" 
"~  ~ii  CHO/4 
"'1  cHo/ s 
.,.."  ,~,  ,~...---,,..' 
rL! 
CHO/6 
nl~  "'la u  '-~-'~  "l'  m ;r  103  ' 
Relotlve  fluorescence  intensity 
E 
e~ 
B 
i.~.  ARH77  "1 
II  In  III  I0 
ft. I 
'""  ~}  ARH77/10 
W-L. ! 
Relatlve 
350 
ARH77/5 
.;..~.~-"  .  .  ..::_  .  .....  ~  .  .. 
" l:''"  ; [~r  r] 
moo  ao  Io  In 
rt,.i 
)O0 
i..'!  ARH77111 
~  -": ",-',?:::,  .....  ,~  .... 
￿9  ￿9  |ll'  I01  Ii 1 
rLI 
fluorescence  Intensity 
Figure  2.  MRP-1/CD9 expression on various cells as defined by mAb M31-15. The expression was determined  by cytofluorometric  analysis. (A) 
DHFR-  CHO and its clones;  (B) ARH77 and its clones. 
further detailed  analysis (Table 1).  MAC10 cells were  also 
cotransfected with control (lacking MRP-1/CD9) DNA of 
pTB1442 and pRc/CMV  DNA,  and when colonies  were 
selected based on G418 resistance, 12 clones were obtained. 
Table  1.  MRP-I/CD9 Contents, Motility, and Cell Growth 
of Transformants and Their Parent MACIO Cells 
Relative  Relative  Relative 
Cell  MRP-1  motility*  growth 
U  %  % 
MAC10  1.0  100  100 
MAC10/1  1.20  _+  0.12  42  82  _+  9* 
MAC10/2  1.10  _+  0#  92  66  _+  10, 
MAC10/5  1.10  _+  0.11  89  76  _+  14 
MAC10/10  1.20  _+  0.1,  51  82  _+  16 
MAC10/13  1.63  _+  0.1  28  63  _+  4 
MAC10/19  1.48  _+  0.25  27  62  +_  12 
MAC10/20  1.15  __  0.06  65  71  _+  17 
Values were determined as described in Materials and M:thods. Data are 
calculated from four independent  experiments, and each value represents 
the mean  •  SD. 
" Average of two independent  experiments. 
t Average of three independent  experiments. 
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The changes in MRP-1 content were not significant  (data 
not shown). 
lvlotility of Various Clones.  Motility of the various clones 
was mainly determined by a cell penetration assay. Cell mo- 
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Figure  3.  The motility of various cells as determined by the cell penetra- 
tion assay. 100/~1 RPMI 1640, 0.1%  FCS was placed in the lower Trans- 
well component. The cells (5  x  104 for DHFR- CHO or 2.5  x  104 
for ARH77) were suspended in 100/A of RPMI 1640, 0.05% FCS, placed 
in the upper chamber,  and cultured for 16 h. Cells penetrating into the 
lower chamber were then counted.  (,'1) DHFR- CHO (P) and its clones 
(I-6, clone numbers); (B) ARH77 (P) and its clones (2-11, clone numbers). 
Each value represents  the mean  _+  SD (bar) (n  =  3). 4 
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Figure  5.  The growth curve  for various  cells. 3 x  104 cells were seeded 
in each well (multidish 24; Nunc), and the plates were incubated at 37~ 
for 7 d. The cells  on the plate  were  harvested  with 0.125% trypsin, 0.01% 
EDTA, and the cell number was counted (Coulter Electronics Inc., Hia- 
leah, FL). MAC10  (O); MAC10/2  (O); MAC10/3 (•);  MAC10/13 (M); 
MAC10/19 (A). Each value represents the mean _+ SD (bar) (n  =  3). 
Figure 4.  The motility of various cells as determined by phagokinesis 
in the gold colloid method. 2  ￿  103 cells harvested with trypsin were 
plated on gold particle-coated coverslips  in a 3.5-cm dish and left in the 
incubator for 16 h. Phagokinetic tracks were visualized under a darkfield 
microscope. (.4) MAC10; (B) MAC10/13. 
tility  was  strongly  suppressed  in  the  clones  of DHFR- 
CHO (Fig. 3 A) and also suppressed in the ARH77 clones 
dependent on the degree of MRP-1/CD9 content (Figs.  2 B 
and 3 B). The motility of the clones derived from MAC10 
cells  was  also  suppressed  dependent  on  the  degree  of the 
MRP-1/CD9 content (Table 1). The motility of the clones 
MAC10/13  and  MAC10/19  was  strongly  suppressed 
('~75%).  The 12 clones obtained by transfection with con- 
trol  DNA  (lacking  MRP-1/CDg)  showed  considerably 
different motility, that is, four clones had markedly high mo- 
tility and four clones had low motility  (data not  shown). 
The average of the relative motility of the 12 clones was 1.22 
_+ 0.66 (mean  _+ SD) times that of the parent MAC10 cells. 
On  the other  hand,  the average of the  14 clones obtained 
by transfection with DNA containing MRP-1/CD9 was 0.60 
+  0.23 (mean  +  SD;/~ <0.005) times that of parent MAC10 
cells (data not shown). This strongly supports the assump- 
tion that the expression of MRP-1/CD9 suppresses cell mo- 
tility.  For Raft cells,  parent Raft cells did not migrate (<10 
cells/well) and no significant  changes in the motility of clones 
were observed (data not shown). The suppression of motility 
was confirmed by a phagokinetic track assay using the clones 
derived from MAC10 cells. As shown in Fig. 4, strong sup- 
pression was confirmed. The average area (n  =  50) of MAC10 
and MAC10/13 cells was 8,366  +  3,250 (mean  _+  SD) and 
2,042  _+  1,101/~m 2,  respectively (p <0.001). 
Cell Adhesion.  The adhesion of cells to fibronectin and 
laminin  was investigated.  An  incubation  time  of 4  h  was 
chosen,  since adhesion  of the cells  to  the plates was weak 
and slow, especially in the case of fibronectin-coated plates 
(data not shown). MAC10/20 cells showed slightly strong 
adhesion to both fibronectin- and laminin-coated plates; how- 
ever, no other clones showed any significant differences com- 
pared  to parental  MAC10 cells  (data not  shown). 
Cell Growth.  The growth of MAC10 and its clones was 
investigated.  The inhibition  of the growth of MAC10 cells 
by mAb M31-15 was weak and ",,15%  at  1-5/~g/ml  (data 
not shown). However, the inhibition in the clones obtained 
from MAC10 cells by transfection with MRP-1/CD9 DNA 
was considerably strong (Fig.  5). The inhibition  of the cell 
growth seemed to be due to the elongation of the doubling 
time, since the inhibition was weak on day I compared with 
days 3, 5, or 7, and the degree of the inhibition was increased 
(Fig. 5). The inhibition  on day 5 is summarized in Table  1. 
The growth of all clones was suppressed and the suppression 
for MAC10/2, MAC10/13, and MAC10/19 was "-'35%. The 
average  of the relative growth of the seven clones (Table  1) 
was 0.73 times that of the parent MAC10 cells. On the other 
hand,  the average  of the 12 clones obtained by transfection 
with control DNA was  1.10 times  that  of parent  MAC10 
cells (data not  shown). 
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Figure 6.  The correlation between  MKP-1/CD9 con- 
tent and the inhibition of cell motility and inhibition of 
cell growth. The data from Table 1 are plotted. (A) MRP- 
1/CD9 content vs. inhibition of cell motility. (B) MRP- 
1/CD9 content vs. inhibition of cell growth. 
Correlation of MRP-1/cDg,  Cell Motility, and Cell Growth. 
For MAC10 and its clones, the inhibition of the motility was 
plotted against the MRP-1/CD9 content (Fig. 6 A), and a 
relatively good correlation  between them was found.  The 
cell motility was markedly suppressed with overexpression 
of MRP-1/CD9. The inhibition of cell growth was also ob- 
served in aU clones, but the correlation between MRP-1/CD9 
content  and  the  degree  of growth  inhibition  was  weak 
(Fig.  6 B). 
Table  2.  Metastatic Potential and Phagokinetic Motility of 
BL6 and Its Transforraants 
No. of metastatic  loci 
Cells  in lung  Mean  •  SD  Motility 
BL6  327,  226,  218,  191, 261, 
203,  127, 193, 187, 230 
BL6/1 60,  44,  58,  83,  49, 
85,  86,  44,  64,  41 
BL6/2 45,  38,  53,  58,  56, 
9,  66,  46,  39,  24 
BL6/3 59,  71,  57,  83,  60, 
72, 26,  81,  75,  19 
BL6/6 42,  126, 91,  77, 77, 
60,  62,  86,  78, 20 
/~m  2 •  SD 
216  _+ 52  8,663  _+ 3,228 
61  _+  18"  5,535  +  2,399* 
43  _+  17"  5,523  •  2,288* 
60 -+  22*  6,077  •  2,328* 
72  _+ 29*  4,440  •  1,885" 
10  s cells of high-metastatic mouse melanoma BL6 (MRP-1/CD9 nega- 
tive) and its four clones (expressing MRP-1/CD9) were injected in- 
travenously into BALB/c nu/nu mice. Metastatic loci in lungs were 
examined after 14 d. Motility was determined by phagokinetic tract as- 
say as described in Materials and Methods. 
* p <o.ool. 
Metastatic Potential of BL6 and Its Transformant.  To deter- 
mine the effect of metastasis by expressing MRP-1/CD9, sev- 
eral human cell lines containing MAC10 cells were tested for 
their ability to make metastatic loci in lung.  However, we 
could not find a high and reproducible metastatic cell line. 
Thus,  the ability of MRP-1/CD9 was evaluated by the use 
of high metastatic mouse melanoma BL6 cell line. BL6 cells 
were transfected with pTB1503 DNA and selected based upon 
resistance  to G418 and we obtained four stable MRP-1/CD9- 
positive clones (seven G418 resistants) from two independent 
experiments.  Cell  motility  and  metastatic  potential  of all 
clones  were  examined  (Table  2).  Both  cell  motility  and 
metastatic potential were suppressed in all clones expressing 
MRP-1/CD9. 
Discussion 
Cell motility is a highly complex process dependent  on 
pericelhlar adhesion molecules such as fibronectin and laminin, 
integrin receptors, cytoskeletal components, and a junctional 
unit  concerning  cytoskeletal  components  and  membrane 
receptors (21, 22). A large variety of growth factors and au- 
tocrine factors have been shown to stimulate cell motility (23), 
which is an essential cellular function and plays a very im- 
portant role in tumor invasion and metastasis, and metastasis 
is among the most important problems in the therapy of the 
patients with various kinds of cancers.  The metastatic dis- 
semination of tumor cells to secondary distinct sites requires 
highly motile behavior, so the regulation of tumor cell mo- 
tility could lead to the suppression of metastasis. 
MRP-1 was identified as motility-related protein using mAb 
M31-15 inhibiting the cell motility (4). The functions of MRP- 
1/CD9  were first  investigated  by the  DNA  transfections 
reported in this paper. The transfections were made with four 
different ceU lines, DHFR-  CHO (hamster; high motility), 
ARH77 (not expressing MRP-1/CD9;  nonadherent;  high 
motility), Raji (not expressing MRP-1/CD9;  nonadherent; 
low motility), and MAC10 (expressing MRP-1/CD9 and used 
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transformant clones were obtained from these cell lines and 
analyzed for cell motility, cell growth, and cell adhesion to 
fibronectin and laminin. In MAC10 cells, MRP-1/CD9 con- 
tent was determined by cell ELISA. The motility was strongly 
suppressed by the (over)expression of MRP-1/CD9  in all 
highly motile cell lines,  such as hamster (DHFR-  CHO) 
and MRP-1/CD9-negative (ARH77) and -positive (MAC10) 
human cell lines. In addition, the degree of motility suppres- 
sion was dependent on the content of MRP-1/CD9  in the 
clones derived from both ARH77 (Figs.  2 B and 3 B) and 
MAC10 cells (Table 1 and Fig.  6 A).  In the cell line with 
low motility (Raji), no significant changes were found (data 
not  shown). These results strongly suggested that  MRP- 
1/CD9  is not a motility-stimulating receptor for the mo- 
tility factors existing in connective tissues  or sera, and that 
it regulates cell motility by an unknown mechanism. The 
possibility remains that MRP-1/CD9  is a receptor for the 
negative signal ligands, but no evidence suggesting this pos- 
sibility has been obtained at present, and this is the subject 
of further investigation. 
The clones from MAC10 cells also  showed strongly in- 
hibited cell growth compared with the parent cells (Fig.  5 
and Table 1), but the correlation between the MRP-1/CD9 
content and the cell growth was weak (Fig. 6 B). Therefore, 
the inhibition of cell growth by transfecting MAC10 cells 
with MRP-1/CD9  DNA may be a secondary effect, since 
mAb M31-15 strongly inhibited cell motility (4) but not cell 
growth.  However, the possibility of a direct effect cannot 
be ruled out, since TAPA-1 (8), a member of the same family, 
strongly inhibits the growth of some cells. Thus, the possi- 
bility that MRP-1/CD9 regulates both cell motility and cell 
growth remains. 
Sequence analysis  revealed  that  MRP-1  (4)  shows high 
similarity with a new family of transmembrane proteins: CD37 
(6), ME491 (7), TAPA-1 (8), CO-029 (9), and Sm23 (10). 
The functions of these proteins are not clear and no studies 
dealing with cell motility have been done. In this paper, we 
clearly showed that MRP-1/CD9  suppressed cell motility 
(Table 1 and Figs. 3, 4, and 6 A). It would be very interesting 
to know whether other proteins in this transmembrane family, 
such as ME491 or CO-029 expressed on solid human tumor 
cell lines, affect cell motility or not. The function of ME491 
and CO-029 is unknown, but recently, Weterman et al. (24) 
reported that pMW4 (ME491)  was expressed highly in less 
metastatic cell lines. This finding is consistent with our ob- 
servation, that is, the expression of MRP-1/CD9-suppressed 
cell motility (Figs.  3,  4,  and 6). 
MRP-1/CD9  was expressed on almost all human solid 
tumor cell lines and weakly expressed or not expressed on 
human normal cells (4). It is very interesting that MRP-1/CD9 
is expressed on cancer cells,  since MRP-1/CD9  suppresses 
cell motility and cell growth, and this should be undesirable 
for cancer cells. Recently, Mohler et al.  (25) reported that 
the existence of cancer cell motility-inhibitory protein in the 
serum-free medium  conditioned by  the  nonmotile,  non- 
metastatic cells. Therefore, cell motility may be regulated by 
both positive and negative signal ligands, and cancer cells may 
have their receptors. It is expected that controlling the ex- 
pression  of  MRP-1/CD9  could  lead  to  suppression  of 
metastasis. Our preliminary experiment (Table 2) showed that 
metastatic potential of mouse melanoma cells was consider- 
ably suppressed by the expression of human MRP-1/CD9. 
We are planning to determine whether or not metastasis is 
also suppressed by the transfection of metastatic human cells 
with MRP-1/CD9  DNA. 
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